Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 3/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 3/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
| ▸ | DDO | Q99489 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 6/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21549766 | 0.80 | IDH1 (0.49) | EIF4A3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL22198962 | 0.80 | TNF (0.43) | TNFRIPK1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL22185210 | 0.79 | PDE3B (0.40) | TRPV1IDH1 | |
| SCHEMBL22185211 | 0.77 | TNF (0.41) | TNFRIPK1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3363264 | 0.76 | DAO (0.61) | TNFRIPK1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL22184925 | 0.75 | DAO (0.59) | DAODDO | |
| SCHEMBL22184879 | 0.74 | EIF4A3 (0.45) | EIF4A3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL22184887 | 0.72 | IDH1 (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21549755 | 0.71 | IDH1 (0.53) | EIF4A3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7122481 | 0.70 | DAO (0.58) | DAOIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | EIF4A3 3498/4885TNF 3164/4885RIPK1 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.